DrugPatentWatch Database Preview

Celgene Company Profile

CELGENE has seven approved drugs.

There are forty-four US patents protecting CELGENE drugs.

There are six hundred and fifty-five patent family members on CELGENE drugs in fifty-one countries and twenty-one supplementary protection certificates in twelve countries.

International Patents:	655
US Patents:	44
Tradenames:	7
Ingredients:	7
NDAs:	7
Patent Litigation for Celgene:	See patent lawsuits for Celgene
PTAB Cases with Celgene as patent owner:	See PTAB cases with Celgene as patent owner

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003		RX	Yes	Yes	7,230,012	➤ Sign Up	Y			➤ Sign Up
Celgene Corp	OTEZLA	apremilast	TABLET;ORAL	205437-001	Mar 21, 2014		RX	Yes	No	7,893,101	➤ Sign Up	Y	Y		➤ Sign Up
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-004	Feb 8, 2013		RX	Yes	Yes	6,561,977	➤ Sign Up				➤ Sign Up
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-002	Jan 17, 2003		RX	Yes	No	6,315,720	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-002	Feb 8, 2013	8,158,653	➤ Sign Up
Celgene	POMALYST	pomalidomide	CAPSULE;ORAL	204026-004	Feb 8, 2013	6,908,432	➤ Sign Up
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-002	Jan 17, 2003	6,908,432	➤ Sign Up
Celgene	THALOMID	thalidomide	CAPSULE;ORAL	020785-002	Jan 17, 2003	6,045,501	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	50 mg and 100 mg	➤ Subscribe	2006-12-18
➤ Subscribe	Capsules	150 mg	➤ Subscribe	2014-02-03
➤ Subscribe	Tablets	10 mg, 20 mg and30 mg	➤ Subscribe	2018-03-22
➤ Subscribe	Capsules	25 mg	➤ Subscribe	2010-07-12
➤ Subscribe	Capsules	2.5 mg and 20 mg	➤ Subscribe	2016-07-12
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2006-09-25
➤ Subscribe	Injection	10 mg/vial	➤ Subscribe	2013-11-05
➤ Subscribe	Capsules	1 mg, 2 mg, 3 mg and 4 mg	➤ Subscribe	2017-02-08
➤ Subscribe	Capsules	5 mg, 10 mg and 15 mg	➤ Subscribe	2010-08-30

Subscribe to access the full database, or try a Free Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0925294	56/2007	Austria	➤ Sign Up	PRODUCT NAME: 1-OXO-2(2,6-DIOXOPIPERIDIN-3-YL)-4- AMINOISOINDOLIN, AUCH 3-(4'AMINOISOINDOLIN-1'-ON)- 1-PIPERIDIN-2,6DION GENANNT, GEGEBENENFALLS IN FORM EINES SAEUREADDITIONSSALZES; REGISTRATION NO/DATE: EU/1/07/391/001 - EU/1/07/391/004 20070614
2105135	122015000013	Germany	➤ Sign Up	PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE (IMNOVID); REGISTRATION NO/DATE: EU/1/13/850 20130805
2105135	C20150005 00140	Estonia	➤ Sign Up	PRODUCT NAME: POMALIDOMIID;REG NO/DATE: EU/1/13/850 08.08.2013
0925294	SPC/GB07/047	United Kingdom	➤ Sign Up	PRODUCT NAME: LENALIDOMIDE (COMMON NAME) 1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-AMINOSOINDOLINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/07/391/001 20070619; UK EU/1/07/391/002 20070619; UK EU/1/07/391/003 20070619; UK EU/1/07/391/004 20070619
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.